Alumis’ (ALMS) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Alumis (NASDAQ:ALMS) in a research report sent to investors on Thursday morning,Benzinga reports.

A number of other brokerages also recently commented on ALMS. Leerink Partnrs upgraded shares of Alumis to a “strong-buy” rating in a research note on Tuesday, July 23rd. Robert W. Baird began coverage on Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective on the stock. HC Wainwright decreased their target price on Alumis from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday. Leerink Partners began coverage on Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 price target for the company. Finally, Morgan Stanley began coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $26.83.

Alumis Stock Down 6.0 %

Shares of Alumis stock opened at $8.85 on Thursday. Alumis has a 52-week low of $8.23 and a 52-week high of $13.53. The business has a 50 day moving average price of $11.22.

Hedge Funds Weigh In On Alumis

A number of institutional investors have recently modified their holdings of ALMS. BNP Paribas Financial Markets acquired a new stake in Alumis during the 3rd quarter worth $27,000. MetLife Investment Management LLC purchased a new stake in shares of Alumis in the third quarter valued at about $89,000. Barclays PLC acquired a new stake in shares of Alumis during the third quarter worth about $197,000. Maven Securities LTD purchased a new position in shares of Alumis during the second quarter worth about $332,000. Finally, State Street Corp acquired a new position in Alumis in the 3rd quarter valued at about $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.